At the time of writing, Adc Therapeutics SA [ADCT] stock is trading at $1.21, up 4.31%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADCT shares have gain 8.04% over the last week, with a monthly amount drifted -33.52%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adc Therapeutics SA [NYSE: ADCT] stock has seen the most recent analyst activity on November 08, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $6. On March 28, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $11 on the stock. JP Morgan upgraded its rating to a Neutral. BofA Securities downgraded its rating to a Underperform and reduced its price target to $2 on April 24, 2023. CapitalOne started tracking with a Overweight rating for this stock on December 06, 2022, and assigned it a price target of $12. In a note dated November 09, 2022, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $14 to $7.
For the past year, the stock price of Adc Therapeutics SA fluctuated between $1.05 and $5.17. Currently, Wall Street analysts expect the stock to reach $9.33 within the next 12 months. Adc Therapeutics SA [NYSE: ADCT] shares were valued at $1.21 at the most recent close of the market. An investor can expect a potential return of 671.07% based on the average ADCT price forecast.
Analyzing the ADCT fundamentals
According to Adc Therapeutics SA [NYSE:ADCT], the company’s sales were 70.84M for trailing twelve months, which represents an 0.71% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.84%, Pretax Profit Margin comes in at -2.21%, and Net Profit Margin reading is -2.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is 0.9 and Total Capital is -0.54. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.61.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1533 points at the first support level, and at 1.0967 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2533, and for the 2nd resistance point, it is at 1.2967.
Ratios To Look Out For
It is important to note that Adc Therapeutics SA [NYSE:ADCT] has a current ratio of 3.82. Further, the Quick Ratio stands at 3.59, while the Cash Ratio is 3.12. Considering the valuation of this stock, the price to sales ratio is 1.69.
Transactions by insiders
Recent insider trading involved Redmile Group, LLC, 10% Owner, that happened on Dec 11 ’24 when 100000.0 shares were purchased. 10% Owner, Redmile Group, LLC completed a deal on Dec 11 ’24 to buy 100000.0 shares. Meanwhile, 10% Owner Redmile Group, LLC sold 25352.0 shares on Dec 04 ’24.
